Kura Oncology surges on initial sales of new leukemia therapy
Kura Oncology (NASDAQ:KURA) reported $5.8 million in net product revenue for the first quarter of 2026, marking the first full period of sales for its acute myeloid leukemia treatment, Komzifti.










